Lisa Junge

A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.

U. Fuhr, M. Kinzig, F. Sörgel, 2020, Journal of clinical pharmacology.

Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment

J. Franklin, U. Fuhr, J. Wolf, 2020, Cancer medicine.

Results on patient-reported outcomes are underreported in summaries of product characteristics for new drugs

N. Mcgauran, T. Kaiser, M. Paulides, 2021, Journal of Patient-Reported Outcomes.

Comparison of the Values of a Novel Exolytic and Two Endolytic Alginate Lyases with Mannuronate Preference for Direct Preparation of Oligosaccharides, Action Modes, and Underlying Catalytic Mechanisms

Lisa Junge, Cheng Yuanyuan, G. Jingyan, 2021 .

A Semiphysiological Population Pharmacokinetic Model for Dynamic Inhibition of Liver and Gut Wall Cytochrome P450 3A by Voriconazole

P. Neuvonen, U. Fuhr, K. Olkkola, 2013, Clinical Pharmacokinetics.